Developer docs
API playgroundTry for free, no card

Search company profiles

NightWare

Full company profile

uuid00035bp

Namestring
NightWare
Legal namestring
NightWare, Inc.
Websiteurl
nightware.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

NightWare is a Delaware-incorporated digital health company headquartered in Hopkins, Minnesota that has developed the first and only FDA-cleared prescription digital therapeutic for the reduction of sleep disturbance related to Nightmare Disorder or PTSD-related nightmares in adults aged 22 and older. The company's core product is an integrated system combining a preprogrammed Apple Watch and iPhone with proprietary, patented AI algorithms that continuously process biometric data (heart rate and body movement) to compute a patient-specific stress index, detect nightmare onset in real time, and deliver personalized vibrotactile stimulation to the wrist that interrupts the nightmare without waking the patient. The system was FDA-designated a Breakthrough Device in 2020 and received marketing authorization in November 2020 under De Novo (DEN200045) as a Class II prescription medical device.

The company's go-to-market is sales-led and prescription-driven, anchored by an enterprise field sales motion through the Veterans Administration (VA) and Department of Defense (DoD) — both selected because of the high concentration of PTSD patients in need and their ability to provide rapid patient access. Beyond the federal channel, NightWare has secured medical policy coverage with Highmark Health BCBS and is actively pursuing Medicare reimbursement through the MCIT Breakthrough CMS pathway as a precursor to broader commercial insurance coverage. The revenue model has historically been a one-time license (hardware kit), and the company is explicitly transitioning toward a recurring revenue model via a patient management program, supported by an ongoing Series C financing at a $10 million pre-money valuation with strategic lead Exit 156 Capital. Customers and partners include the Minneapolis VA, Tampa VA, Walter Reed National Military Medical Center (running a randomized controlled trial), Highmark Health BCBS, and Apple (hardware platform), with 2024 launches adding commercial insurance pilots with fire and police departments and a national VA Pathfinder Innovation Pilot.

NightWare is venture-backed and early-stage, with 1-10 employees, total disclosed funding of roughly $7.5 million across multiple rounds between 2019 and 2026, and revenue not publicly disclosed. Leadership transitioned in July 2024 when Matthew Tucker (formerly Chief Commercial Officer and board member, with prior executive roles at Baxter Healthcare, Mylan Pharmaceuticals, and Highmark Health) assumed the CEO role from founder Grady Hannah, who moved to Chief Product Officer — a change that signals a shift from research-led to commercial-execution-led operating posture. The company is currently running a pivotal randomized, double-blind, placebo-controlled trial (NCT04040387) designed to enroll up to 480 adults with PTSD and nightmares, with clinical efficacy already demonstrated through a 3.3-point PSQI-A improvement versus 1.4 points for sham.

Short descriptiontext

NightWare is a digital health company that has developed the first and only FDA-cleared prescription digital therapeutic using Apple Watch and proprietary AI to detect and interrupt nightmares in adults 22+ with Nightmare Disorder or PTSD-related nightmares, initially serving VA, DoD, and select commercial populations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription digital therapeutic, sleep disorder treatment, PTSD nightmare therapy, vibrotactile sleep technology, FDA cleared device
Industry5 codes
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAEAI
Crisis Support, Suicide Prevention & Acute Behavioral Triage Platforms
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYCRACAIAG
Sleep Tech Wearables
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Therapeutics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Prescription Digital Therapeutic Device
TypeOne Time License
Description

NightWare sells an FDA-cleared prescription digital therapeutic system that includes a preprogrammed Apple Watch and iPhone. The company is expanding toward a recurring revenue model through its patient management program while pursuing Medicare and commercial insurance coverage.

globenewswire.com
2Insurance Reimbursement
TypeSubscription Recurring
Description

The company is actively seeking coverage by Medicare through the MCIT Breakthrough CMS pathway. Upon Medicare coverage determination, they will approach private insurance companies. NightWare has medical policy coverage with Highmark Health BCBS. VA and DoD provide access to patients.

nightware.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

NightWare develops and sells the NightWare Digital Therapeutic System, an FDA-cleared Class II prescription digital therapeutic for adults 22 and older with Nightmare Disorder or PTSD-related nightmares. The system pairs a preprogrammed Apple Watch and iPhone with proprietary AI that monitors heart rate and motion, detects nightmares in real time via a patient-specific stress index, and delivers personalized vibrotactile stimulation to interrupt nightmares without waking the user. The product is prescription-only and is sold through healthcare providers and institutional payers including the VA, DoD, and Highmark Health BCBS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 3.2-point improvement on Pittsburgh Sleep Quality Index (PSQI) in ongoing randomized controlled trial, exceeding minimal clinically important difference
+4 more records
Product overview1 text field

NightWare offers a single unified product: the NightWare Digital Therapeutic System. This is a prescription digital therapeutic that combines a preprogrammed Apple Watch and iPhone (provided as part of an all-inclusive kit) with proprietary AI-powered software. The system monitors sleep through Apple Watch biometric sensors, uses AI algorithms to detect nightmares in real time, and delivers customized vibrotactile stimulation to interrupt nightmares without waking the patient. It is FDA-cleared (November 2020) and designated as a Breakthrough Device for the reduction of sleep disturbance related to Nightmare Disorder or PTSD-related nightmares in adults 22 and older.

Product and service1 record
1NightWare Digital Therapeutic System
CategoryDigital Therapeutics / Sleep Medicine
Description

FDA-cleared Class II prescription digital therapeutic that pairs a preprogrammed Apple Watch and iPhone with proprietary AI software to monitor heart rate and motion during sleep, detect nightmares in real time via a patient-specific stress index, and deliver personalized vibrotactile stimulation to interrupt nightmares without waking the patient. Indicated for adults 22+ with Nightmare Disorder or PTSD-related nightmares and sold only via clinician prescription.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Walter Reed National Military Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Walter Reed is conducting a clinical trial of NightWare in a randomized controlled trial to establish safety and efficacy of the NightWare digital therapeutic system for treatment of nightmare disorder associated with PTSD-related sleep disturbance.

nightware.com
2Minneapolis Veterans Affairs Health Care System
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Primary site for NightWare's randomized, double-blind, placebo-controlled clinical trial (NW101002) enrolling adults with PTSD and nightmares. Conducted at the Minneapolis VA Health Care System.

nightware.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Second site for NightWare's pivotal trial continuing the clinical development program following Breakthrough Device designation.

Strategic tierCoreTypeTechnology or Integration
Description

NightWare uses Apple Watch as the hardware platform for its FDA-cleared prescription digital therapeutic, utilizing the Apple Watch heart monitor sensor and other biometric sensors to detect nightmares and deliver vibrotactile stimulation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Big Health (maker of Sleepio) is a prescription digital therapeutic for insomnia and anxiety, the closest direct competitor in FDA-cleared sleep DTx. Both companies target sleep disturbance with prescription digital therapeutics and pursue payer coverage through employer and health plan channels.

TypeDirect peer
Description

Akili Interactive pioneered the prescription digital therapeutic category with FDA clearance for EndeavorRx (ADHD). Both companies pursue the prescription DTx regulatory pathway via FDA SaMD/Class II authorization and rely on adaptive digital interventions to treat cognitive/behavioral conditions.

3Pear Therapeutics
TypeDirect peer
Description

Pear Therapeutics was the leading prescription DTx company (reSET, reSET-O, Somryst for chronic insomnia) before its 2023 bankruptcy. Pear is a direct comparable for NightWare's commercial trajectory challenges and validates the prescription DTx business model structure.

4Calm Health
TypeBroad incumbent
Description

Calm Health extends the consumer Calm app into clinically-validated mental health and sleep programs, including B2B employer and health plan distribution. Overlaps with NightWare in sleep and mental health treatment, though primarily a self-pay/consumer model vs. NightWare's prescription model.

TypeBroad incumbent
Description

Headspace Health (now part of Bending Spoons) provides mental health and sleep support via employer and health plan channels. Comparable in targeting sleep/mental health through digital interventions and pursuing B2B distribution, though via self-guided content rather than prescription FDA pathway.

TypeEmerging player
Description

Limbic is an AI-powered digital mental health platform with NHS approval in the UK serving as a CE-marked SaMD for mental health. Comparable as a clinically-validated, AI-driven mental health digital therapeutic with regulatory pathway focus.

TypeEmerging player
Description

Oura is a consumer sleep and recovery wearable ring with biometric tracking (heart rate, sleep stages) comparable to Apple Watch biometrics in NightWare's stack. Comparable through sleep-tracking wearable technology and consumer health data platform, though consumer-only and not a prescription therapeutic.

TypeEmerging player
Description

Eight Sleep makes the Pod smart mattress cover with biometric sleep tracking and temperature modulation. Comparable as a sleep technology company using sensors and AI to intervene during sleep, though hardware-form-factor differs and not a prescription therapeutic.

9CureApp
TypeEmerging player
Description

CureApp is a Japanese prescription digital therapeutic company with multiple FDA-equivalent approvals for hypertension, nicotine dependence, and other conditions. Comparable as a prescription SaMD DTx company navigating payer coverage in non-US healthcare systems.

TypeEmerging player
Description

BehaVR (now Sumitomo Pharma-backed) develops prescription digital therapeutics using VR and immersive experiences for mental health conditions including anxiety, depression, and PTSD. Comparable in VR/digital-therapeutic approach to behavioral health conditions, including PTSD overlapping with NightWare's indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NightWare

Digital Therapeuticsnightware.com

NightWare is a digital health company that has developed the first and only FDA-cleared prescription digital therapeutic using Apple Watch and proprietary AI to detect and interrupt nightmares in adults 22+ with Nightmare Disorder or PTSD-related nightmares, initially serving VA, DoD, and select commercial populations.

What NightWare does

NightWare is a Delaware-incorporated digital health company headquartered in Hopkins, Minnesota that has developed the first and only FDA-cleared prescription digital therapeutic for the reduction of sleep disturbance related to Nightmare Disorder or PTSD-related nightmares in adults aged 22 and older. The company's core product is an integrated system combining a preprogrammed Apple Watch and iPhone with proprietary, patented AI algorithms that continuously process biometric data (heart rate and body movement) to compute a patient-specific stress index, detect nightmare onset in real time, and deliver personalized vibrotactile stimulation to the wrist that interrupts the nightmare without waking the patient. The system was FDA-designated a Breakthrough Device in 2020 and received marketing authorization in November 2020 under De Novo (DEN200045) as a Class II prescription medical device.

The company's go-to-market is sales-led and prescription-driven, anchored by an enterprise field sales motion through the Veterans Administration (VA) and Department of Defense (DoD) — both selected because of the high concentration of PTSD patients in need and their ability to provide rapid patient access. Beyond the federal channel, NightWare has secured medical policy coverage with Highmark Health BCBS and is actively pursuing Medicare reimbursement through the MCIT Breakthrough CMS pathway as a precursor to broader commercial insurance coverage. The revenue model has historically been a one-time license (hardware kit), and the company is explicitly transitioning toward a recurring revenue model via a patient management program, supported by an ongoing Series C financing at a $10 million pre-money valuation with strategic lead Exit 156 Capital. Customers and partners include the Minneapolis VA, Tampa VA, Walter Reed National Military Medical Center (running a randomized controlled trial), Highmark Health BCBS, and Apple (hardware platform), with 2024 launches adding commercial insurance pilots with fire and police departments and a national VA Pathfinder Innovation Pilot.

NightWare is venture-backed and early-stage, with 1-10 employees, total disclosed funding of roughly $7.5 million across multiple rounds between 2019 and 2026, and revenue not publicly disclosed. Leadership transitioned in July 2024 when Matthew Tucker (formerly Chief Commercial Officer and board member, with prior executive roles at Baxter Healthcare, Mylan Pharmaceuticals, and Highmark Health) assumed the CEO role from founder Grady Hannah, who moved to Chief Product Officer — a change that signals a shift from research-led to commercial-execution-led operating posture. The company is currently running a pivotal randomized, double-blind, placebo-controlled trial (NCT04040387) designed to enroll up to 480 adults with PTSD and nightmares, with clinical efficacy already demonstrated through a 3.3-point PSQI-A improvement versus 1.4 points for sham.

NightWare firmographics

Firmographics
Name
NightWare
Legal name
NightWare, Inc.
Website
https://nightware.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
NightWare is a digital health company that has developed the first and only FDA-cleared prescription digital therapeutic using Apple Watch and proprietary AI to detect and interrupt nightmares in adults 22+ with Nightmare Disorder or PTSD-related nightmares, initially serving VA, DoD, and select commercial populations.
Ownership category
akta.pro rank

NightWare industry classification

Industry
Product category
Digital Therapeutics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAEAI
Crisis Support, Suicide Prevention & Acute Behavioral Triage Platforms
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYCRACAIAG
Sleep Tech Wearables

Keywords

  • Prescription digital therapeutic
  • Sleep disorder treatment
  • PTSD nightmare therapy
  • Vibrotactile sleep technology
  • FDA cleared device

Where NightWare is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Offices2 records

Markets served

NightWare business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Prescription Digital Therapeutic Device: NightWare sells an FDA-cleared prescription digital therapeutic system that includes a preprogrammed Apple Watch and iPhone. The company is expanding toward a recurring revenue model through its patient management program while pursuing Medicare and commercial insurance coverage.
  2. Insurance Reimbursement: The company is actively seeking coverage by Medicare through the MCIT Breakthrough CMS pathway. Upon Medicare coverage determination, they will approach private insurance companies. NightWare has medical policy coverage with Highmark Health BCBS. VA and DoD provide access to patients.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

NightWare product offering

Product offering

Core offering

NightWare develops and sells the NightWare Digital Therapeutic System, an FDA-cleared Class II prescription digital therapeutic for adults 22 and older with Nightmare Disorder or PTSD-related nightmares. The system pairs a preprogrammed Apple Watch and iPhone with proprietary AI that monitors heart rate and motion, detects nightmares in real time via a patient-specific stress index, and delivers personalized vibrotactile stimulation to interrupt nightmares without waking the user. The product is prescription-only and is sold through healthcare providers and institutional payers including the VA, DoD, and Highmark Health BCBS.

Product overview

NightWare offers a single unified product: the NightWare Digital Therapeutic System. This is a prescription digital therapeutic that combines a preprogrammed Apple Watch and iPhone (provided as part of an all-inclusive kit) with proprietary AI-powered software. The system monitors sleep through Apple Watch biometric sensors, uses AI algorithms to detect nightmares in real time, and delivers customized vibrotactile stimulation to interrupt nightmares without waking the patient. It is FDA-cleared (November 2020) and designated as a Breakthrough Device for the reduction of sleep disturbance related to Nightmare Disorder or PTSD-related nightmares in adults 22 and older.

Differentiator

Problem solved

Functional benefit

Products and services

  • NightWare Digital Therapeutic System FDA-cleared Class II prescription digital therapeutic that pairs a preprogrammed Apple Watch and iPhone with proprietary AI software to monitor heart rate and motion during sleep, detect nightmares in real time via a patient-specific stress index, and deliver personalized vibrotactile stimulation to interrupt nightmares without waking the patient. Indicated for adults 22+ with Nightmare Disorder or PTSD-related nightmares and sold only via clinician prescription.

Quantifiable outcome

  • 3.2-point improvement on Pittsburgh Sleep Quality Index (PSQI) in ongoing randomized controlled trial, exceeding minimal clinically important difference
  • +4 more outcomes

Companies that use NightWare

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles4 records

NightWare technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

NightWare partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Walter Reed National Military Medical CentercoreStrategic or Co-development PartnerWalter Reed is conducting a clinical trial of NightWare in a randomized controlled trial to establish safety and efficacy of the NightWare digital therapeutic system for treatment of nightmare disorder associated with PTSD-related sleep disturbance.
  • Minneapolis Veterans Affairs Health Care SystemcoreStrategic or Co-development PartnerPrimary site for NightWare's randomized, double-blind, placebo-controlled clinical trial (NW101002) enrolling adults with PTSD and nightmares. Conducted at the Minneapolis VA Health Care System.
  • Tampa VA FacilityminorStrategic or Co-development PartnerSecond site for NightWare's pivotal trial continuing the clinical development program following Breakthrough Device designation.
  • ApplecoreTechnology or IntegrationNightWare uses Apple Watch as the hardware platform for its FDA-cleared prescription digital therapeutic, utilizing the Apple Watch heart monitor sensor and other biometric sensors to detect nightmares and deliver vibrotactile stimulation.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

NightWare competitors and assessment

Company assessment

Direct peers

  • Big Health: Big Health (maker of Sleepio) is a prescription digital therapeutic for insomnia and anxiety, the closest direct competitor in FDA-cleared sleep DTx. Both companies target sleep disturbance with prescription digital therapeutics and pursue payer coverage through employer and health plan channels.
  • Akili Interactive: Akili Interactive pioneered the prescription digital therapeutic category with FDA clearance for EndeavorRx (ADHD). Both companies pursue the prescription DTx regulatory pathway via FDA SaMD/Class II authorization and rely on adaptive digital interventions to treat cognitive/behavioral conditions.
  • Pear Therapeutics: Pear Therapeutics was the leading prescription DTx company (reSET, reSET-O, Somryst for chronic insomnia) before its 2023 bankruptcy. Pear is a direct comparable for NightWare's commercial trajectory challenges and validates the prescription DTx business model structure.

Broad incumbents

  • Calm Health: Calm Health extends the consumer Calm app into clinically-validated mental health and sleep programs, including B2B employer and health plan distribution. Overlaps with NightWare in sleep and mental health treatment, though primarily a self-pay/consumer model vs. NightWare's prescription model.
  • Headspace Health: Headspace Health (now part of Bending Spoons) provides mental health and sleep support via employer and health plan channels. Comparable in targeting sleep/mental health through digital interventions and pursuing B2B distribution, though via self-guided content rather than prescription FDA pathway.

Emerging players

  • Limbic: Limbic is an AI-powered digital mental health platform with NHS approval in the UK serving as a CE-marked SaMD for mental health. Comparable as a clinically-validated, AI-driven mental health digital therapeutic with regulatory pathway focus.
  • Oura: Oura is a consumer sleep and recovery wearable ring with biometric tracking (heart rate, sleep stages) comparable to Apple Watch biometrics in NightWare's stack. Comparable through sleep-tracking wearable technology and consumer health data platform, though consumer-only and not a prescription therapeutic.
  • Eight Sleep: Eight Sleep makes the Pod smart mattress cover with biometric sleep tracking and temperature modulation. Comparable as a sleep technology company using sensors and AI to intervene during sleep, though hardware-form-factor differs and not a prescription therapeutic.
  • CureApp: CureApp is a Japanese prescription digital therapeutic company with multiple FDA-equivalent approvals for hypertension, nicotine dependence, and other conditions. Comparable as a prescription SaMD DTx company navigating payer coverage in non-US healthcare systems.
  • BehaVR: BehaVR (now Sumitomo Pharma-backed) develops prescription digital therapeutics using VR and immersive experiences for mental health conditions including anxiety, depression, and PTSD. Comparable in VR/digital-therapeutic approach to behavioral health conditions, including PTSD overlapping with NightWare's indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NightWare social profiles

Digital presence

NightWare compliance and trust

Trust signal

Compliance1 record

NightWare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NightWare leadership team

Management profile

Number of profiles

Profiles7 records

NightWare funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NightWare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NightWare

What does NightWare do?

NightWare develops and sells the NightWare Digital Therapeutic System, an FDA-cleared Class II prescription digital therapeutic for adults 22 and older with Nightmare Disorder or PTSD-related nightmares. The system pairs a preprogrammed Apple Watch and iPhone with proprietary AI that monitors heart rate and motion, detects nightmares in real time via a patient-specific stress index, and delivers personalized vibrotactile stimulation to interrupt nightmares without waking the user. The product is prescription-only and is sold through healthcare providers and institutional payers including the VA, DoD, and Highmark Health BCBS.

Is NightWare a public or private company?

NightWare is a private company. It is classified as venture growth investor backed and is currently operating.

When was NightWare founded?

NightWare was founded in 2017. It employs 1 to 10 people.

Where is NightWare based?

NightWare is headquartered in Minneapolis, United States, in the North America region.

How does NightWare make money?

Two revenue lines are on record. Prescription Digital Therapeutic Device is the primary driver. The others are insurance Reimbursement.

Who are NightWare's main competitors?

Direct peers on record are Big Health, Akili Interactive and Pear Therapeutics. Broad incumbents are Calm Health and Headspace Health. Emerging players are Limbic, Oura, Eight Sleep, CureApp and BehaVR.

Does NightWare have an API?

No public API is recorded for NightWare.

What industry is NightWare in?

NightWare's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Sleep ReviewNightWare Announces Strategic Investment PartnershipNightWare Inc and Exit 156 Capital announced a strategic investment partnership as part of NightWare's ongoing Series C financing, raised at a $10 million pre-money valuation with $1.4 million already secured. The FDA-cleared prescription digital therapeutic for PTSD-related nightmare disorder uses an Apple Watch and AI to deliver personalized vibrotactile stimulation during sleep to interrupt nightmares. Investment proceeds will accelerate the national VA Pathfinder Innovation Pilot, scale employer-group commercial insurance pilots with fire and police departments, and support regulatory submission to Israel for international market entry.GlobeNewswireEXIT 156 CAPITAL AND NIGHTWARE ANNOUNCE STRATEGIC INVESTMENT PARTNERSHIPNightWare, Inc., a Minneapolis-based digital health company, announced a strategic investment partnership with Exit 156 Capital in its ongoing Series C financing round. The Series C is being raised at a $10 million pre-money valuation, with $1.4 million already secured and $2.0 million in equity remaining available to qualified investors. The investment will accelerate NightWare's national VA Pathfinder Innovation Pilot, scale commercial insurance pilots with first responder organizations, advance proprietary hardware development, and expand the company's patient management program toward a recurring revenue model.SecSEC FORM DNightWare, Inc., a Delaware-incorporated health care company headquartered in Hopkins, Minnesota, filed a Form D notice with the SEC on March 6, 2026, for an exempt offering of equity securities under Rule 506(b). The company is seeking to raise up to $2,040,000 and has already sold $250,000 of the offering, leaving $1,790,000 remaining to be sold. The filing lists five executive officers and directors including CEO Matthew Tucker, with the first sale occurring on February 24, 2026.ZME ScienceYour Next Therapist Could be a Video Game or a Wearable and It Might Actually WorkA peer-reviewed study examines digital therapeutics like NightWare, Freespira, EndeavorRx, and Sleepio, which are FDA-cleared or NICE-approved for conditions such as PTSD, panic disorder, ADHD, and insomnia. The authors warn that privacy, access, and long-term efficacy remain unresolved issues. They call for stronger encryption, equitable design, and longer trials.NatureAnalyzing metaverse-based digital therapies, their effectiveness, and potential risks in mental healthcareThis article presents a systematic literature review and case study examining metaverse-based digital therapies in mental healthcare, evaluating four applications: NightWare, Freespira, EndeavorRx, and Sleepio. The research found that these digital therapeutics demonstrate clinical validation for conditions including PTSD, anxiety, ADHD, and insomnia, with effectiveness rates ranging from 40% to 76% improvement in patients. However, the study identifies persistent concerns around data privacy, cybersecurity risks, digital divide, accessibility, and long-term efficacy that require further research and regulatory attention.American City Business JournalsNightWare raising crowdfunding capital for PTSD-fighting techNightWare Inc. is raising up to $1.23 million on StartEngine to expand its Apple Watch-based nightmare-disruption technology for PTSD. The company has made $4.3 million in sales this year and plans to use funds for clinical trials and access expansion.NeurologyadvisorPrescription Digital Therapeutics for Mental Health: A New Era in PsychiatryAn overview article reviews FDA-cleared prescription digital therapeutics for mental health, including DaylightRx for generalized anxiety disorder, Rejoyn for major depressive disorder, MamaLift Plus for postpartum depression, NightWare for sleep disturbance, EndeavorRx for ADHD, and reSET and reSET-O for substance use disorders. It notes clinician concerns over patient privacy, insurance coverage, broadband access, and limited physician awareness.PR NewswireRapid-Acting Mental Health Treatment Summit Aims to Lead the Conversation on What's Next in Mental HealthBrainFutures and The Frontier Psychiatrists Substack announced they will co-host the Rapid-Acting Mental Health Treatment 2024 summit on January 7, 2024, in San Francisco, timed to coincide with the JP Morgan Healthcare Conference. The event will gather mental health leaders to discuss emerging rapid-acting treatments including psychedelic-assisted therapy, FDA-Breakthrough digital therapeutics like NightWare, and the SAINT Neuromodulation System by Magnus Medical. Major sponsors include NightWare, Magnus Medical, Acacia Mental Health, Videra Health, and MelEos Group, with executives from these companies among the announced speakers.HtdhealthDigital Therapeutics explainedAn explainer article defines digital therapeutics as FDA-regulated software interventions that deliver evidence-based medical care without clinician involvement per session, classifying them as Software as Medical Device. It cites a $56 billion market projection by 2025, over 100 pipeline solutions, and companies like Pear Therapeutics, Floreo, NightWare and EndeavorRX. It also notes reimbursement uncertainty, provider unfamiliarity, and the FDA's Breakthrough and Safer Technologies programs.